Schizophrenia Clinical Trial
Official title:
EXPLORATION OF THE SOCIAL COGNITION IN ADOLESCENTS WITH A Dissociative Disorder OR AUTISM SPECTRUM
The schizophrenic disorders and pervasive developmental disorders are neurodevelopmental
disorders distinct origin who share common challenges to engage and maintain social
relationships and mutual disturbances of affective contact. An important issue of research
is to determine the cognitive and brain mechanisms underlying social disability in these two
pathologies. Several lines of social cognition have been systematically explored: the
perception of emotions, the ability to attribute intentionality and mental states to others
(theory of mind), the understanding of social situations in different contexts. We made the
observation today that research findings clearly in the field of autism and schizophrenic
disorders that converge on common patterns neurocognitive abnormalities. Consequently, many
programs support published today use the same therapeutic targets and the same tools in both
pathologies. This raises two questions of science: (1) whether the disorders of social
cognition reported in the field of autism and schizophrenia are "specific deficit" and not
"specific condition", that is to say they are inherent social disadvantage whatever
condition or (2) if these disorders of social cognition is a pattern common to autism and
schizophrenia but are the result of specific neurocognitive mechanisms and different in each
these pathologies. Systematic exploration of these issues is a current issue for
understanding the pathophysiological borders between the two neurodevelopmental disorders
but also to better define the potential targets of therapeutic strategies,
psycho-educational and remediation of disorders of social cognition in autism and
schizophrenia.
Main objective: To compare clinical cognitive profiles in adolescents with a schizophrenic
disorder, autistic or healthy in the three areas of social cognition: perception of
emotions, attribution of intentions to others (theory of mind) and style attribution. We
shall constitute three population groups of patients, a group of patients meeting the
diagnosis of schizophrenia, a group of patients with autism and a control group (healthy
subjects).
The schizophrenic disorders and pervasive developmental disorders are neurodevelopmental
disorders distinct origin who share common challenges to engage and maintain social
relationships and mutual disturbances of affective contact. An important issue of research
is to determine the cognitive and brain mechanisms underlying social disability in these two
pathologies. Several lines of social cognition have been systematically explored: the
perception of emotions, the ability to attribute intentionality and mental states to others
(theory of mind), the understanding of social situations in different contexts. We made the
observation today that research findings clearly in the field of autism and schizophrenic
disorders that converge on common patterns neurocognitive abnormalities. Consequently, many
programs support published today use the same therapeutic targets and the same tools in both
pathologies. This raises two questions of science: (1) whether the disorders of social
cognition reported in the field of autism and schizophrenia are "specific deficit" and not
"specific condition", that is to say they are inherent social disadvantage whatever
condition or (2) if these disorders of social cognition is a pattern common to autism and
schizophrenia but are the result of specific neurocognitive mechanisms and different in each
these pathologies. Systematic exploration of these issues is a current issue for
understanding the pathophysiological borders between the two neurodevelopmental disorders
but also to better define the potential targets of therapeutic strategies,
psycho-educational and remediation of disorders of social cognition in autism and
schizophrenia.
Main objective: To compare clinical cognitive profiles in adolescents with a schizophrenic
disorder, autistic or healthy in the three areas of social cognition: perception of
emotions, attribution of intentions to others (theory of mind) and style attribution. We
shall constitute three population groups of patients, a group of patients meeting the
diagnosis of schizophrenia, a group of patients with autism and a control group (healthy
subjects).
Inclusion criteria: patients aged 12 to 18, with a verbal IQ greater than or equal to 70, a
DSM-IV diagnosis of autism and / or schizophrenia.
Assessment instruments: (1) clinical assessment instruments using standardized structured
interviews that have already shown good sensitivity in our preliminary studies (2)
techniques neuro-social cognition scientifically validated by the expert group of the ANR we
are partners.
The study of active files and preliminary results, we can estimate the population to 20
patients per group, a total of 60 patients.
The originality of this study focuses on the ability to compare two populations in the same
field of social cognition in three dimensions, which hitherto have been explored separately
in the literature. The expected results are a range of prevention and treatment of major
psychiatric children and adolescents because they help define therapeutic targets specific
to each population
;
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |